文献速递泌尿生殖与妇科肿瘤放疗

HYPRO试验7年结果:前列腺癌大分割与常规分割放疗对比

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-05

HYPRO是一项多中心、随机、开放标签、III期试验,比较中高危局限期前列腺癌大分割放疗(HF,64.6 Gy/19次)与常规分割放疗(CF,78.0 Gy/39次)。研究未证实大分割放疗在肿瘤控制方面优于常规分割放疗。

要点

  • 中高危局限期前列腺癌大分割放疗7年无复发生存率71.7%,常规分割67.6%,差异无统计学意义。
  • 大分割放疗总生存率80.8%,常规分割77.6%,两组间差异无统计学意义。
  • 基于α/β=1.5 Gy假设,大分割组等效生物剂量(EQD2)为90.4 Gy,高于常规分割组的78.0 Gy。

核心结论

  • 7年无复发生存结果证实,大分割放疗组假设的剂量提升并未转化为优于常规分割放疗的肿瘤控制。

研究设计与样本

  • 多中心、随机、开放标签、III期HYPRO试验,纳入中高危T1b-T4NX-N0MX-M0局限期前列腺癌患者。
  • 患者按1:1随机接受大分割放疗(64.6 Gy/19次)或常规分割放疗(78.0 Gy/39次)。
  • 共入组820例患者,804例可评估(HF组407例,CF组397例),中位随访89个月(四分位距83-99)。

主要发现

  • 7年治疗失败共220例(27.4%),HF组107例(26.3%),CF组113例(28.5%)。
  • 804例患者中537例(67%)接受同期雄激素剥夺治疗,中位持续时间32个月(四分位距10-44)。

关键数值与推荐

  • 大分割放疗方案:64.6 Gy分19次;常规分割放疗方案:78.0 Gy分39次。
  • 基于前列腺癌α/β比值1.5 Gy估算,HF组EQD2为90.4 Gy,CF组为78.0 Gy。

临床怎么用

  • 在中高危局限期前列腺癌中,大分割放疗(64.6 Gy/19次)可作为常规分割放疗的替代选择,但并未显示更优的肿瘤控制。
  • 同期雄激素剥夺治疗使用比例较高(67%),可能影响无复发生存结局的解读。

局限性

  • 同期长期雄激素剥夺治疗的高频率使用可能对无复发生存产生实质性影响。
  • 本文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the multicenter, phase 3, HYpofractionated irradiation for PROstate cancer trial, hypofractionated (HF) radiation therapy was compared with conventionally fractionated (CF) radiation therapy. In previous reports, we could not demonstrate the postulated superiority of hypofractionation in terms of relapse-free survival at 5 years. The frequent use of long-term androgen deprivation therapy might have had substantial effects on relapse-free survival. In the current analysis, we provide updated 7-year relapse-free survival outcomes. METHODS AND MATERIALS: We enrolled patients with intermediate- to high-risk T1b-T4NX-N0MX-M0 localized prostate cancer. Patients were randomly assigned (1:1) to either HF (64.6 Gy in 19 fractions) or CF (78.0 Gy in 39 fractions) radiation therapy. Based on an estimated α/β ratio for prostate cancer of 1.5 Gy, the EQD2 was 90.4 Gy for HF versus 78.0 Gy for CF radiation therapy. The primary endpoint of the present analysis is relapse-free survival at 7 years. RESULTS: A total of 820 patients were enrolled, of whom 804 were assessable for the current evaluation (407 HF versus 397 CF). Median follow-up was 89 months (interquartile range, 83-99). Concomitant androgen deprivation therapy was prescribed for 537 (67%) of 804 patients for a median duration of 32 months (interquartile range, 10-44). Treatment failure at 7 years was reported in 220 (27.4%) of 804 patients, 107 (26.3%) in HF versus 113 (28.5%) in CF radiation therapy. Seven-year relapse-free survival was 71.7% (95% confidence interval [CI], 66.4-76.4) for HF versus 67.6% (95% CI, 62.0-72.5) for CF (P = .52). Overall survival was 80.8% (95% CI, 76.5-84.4) in HF versus 77.6% (95% CI, 73.0-81.5) in CF radiation therapy (P = .17). CONCLUSIONS: The current results of 7-year relapse-free survival confirmed our previous findings that the hypothesized dose escalation in the HF arm did not translate to superior tumor control compared with the CF arm.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. de Vries KC, Wortel RC, Oomen-de Hoop E, et al. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31593756. doi:10.1016/j.ijrobp.2019.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。